Cenegermin

Cenegermin (planned brand names Oxervate, Sentinel), also known as recombinant human nerve growth factor (rhNGF), is a recombinant form of human nerve growth factor (NGF). It was approved in the European Union as an eye drop formulation for the treatment of moderate or severe neurotrophic keratitis in adults on 6 July 2017.[2][3][1] As a recombinant form of NGF, cenegermin is a peripherally selective agonist of the TrkA and LNGFR (p75NTR) which must be administered parenterally.[3] In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.[3] It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.[3]

Cenegermin
Clinical data
Trade namesOxervate, Sentinel
Other namesRecombinant human nerve growth factor; rhNGF; human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli[1]
Routes of
administration		Eye drops
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • None
UNII
KEGG
Chemical and physical data
FormulaC583H908N166O173S8
Molar mass13266.94 g/mol g·mol−1

See also

References
  1. http://www.who.int/medicines/publications/druginformation/issues/77_INN_Recommended_List.pdf
  2. "Authorisation details". European Medicines Agency. Retrieved 19 February 2018.
  3. http://adisinsight.springer.com/drugs/800035751



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.